1.Delhommeau, F, Dupont, S, Della Valle, V, James, C, Trannoy, S, Masse, A, et al. Mutation in TET2 in myeloid cancers. New England Journal of Medicine. 2009;360(22):2289–301.
2.Schaub, FX, Looser, R, Li, S, Hao-Shen, H, Lehmann, T, Tichelli, A, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003–7.
3.Kralovics, R, Stockton, DW, Prchal, JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102(10):3793–6.
4.Bellanne-Chantelot, C, Chaumarel, I, Labopin, M, Bellanger, F, Barbu, V, De Toma, C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346–52.
5.Rumi, E, Passamonti, F, Della Porta, MG, Elena, C, Arcaini, L, Vanelli, L, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. Journal of Clinical Oncology. 2007;25(35):5630–5.
6.Landgren, O, Goldin, LR, Kristinsson, SY, Helgadottir, EA, Samuelsson, J, Bjorkholm, M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199–204.
7.Swierczek, SI, Agarwal, N, Nussenzveig, RH, Rothstein, G, Wilson, A, Artz, A, et al. Hematopoiesis is not clonal in healthy elderly women. Blood. 2008;112(8):3186–93.
8.Prchal, JF, Axelrad, AA. Letter: Bone-marrow responses in polycythemia vera. New England Journal of Medicine. 1974;290(24):1382.
9.Kapralova, K, Lanikova, L, Lorenzo, F, Song, J, Horvathova, M, Divoky, V, et al. RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood. 2014;123(3):391–4.
10.Levine, RL, Pardanani, A, Tefferi, A, Gilliland, DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer. 2007;7(9):673–83.
11.Kralovics, R, Guan, Y, Prchal, JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology. 2002;30(3):229–36.
12.Yildirim, E, Kirby, JE, Brown, DE, Mercier, FE, Sadreyev, RI, Scadden, DT, et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013;152(4):727–42.
13.Spivak, JL, Considine, M, Williams, DM, Talbot, CC, Jr., Rogers, O, Moliterno, AR, et al. Two clinical phenotypes in polycythemia vera. New England Journal of Medicine. 2014;371(9):808–17.
14.Ranjan, A, Penninga, E, Jelsig, AM, Hasselbalch, HC, Bjerrum, OW. Inheritance of the chronic myeloproliferative neoplasms. A systematic review. Clinical Genetics. 2013;83(2):99–107.
15.Saint-Martin, C, Leroy, G, Delhommeau, F, Panelatti, G, Dupont, S, James, C, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628–32.
16.Olcaydu, D, Rumi, E, Harutyunyan, A, Passamonti, F, Pietra, D, Pascutto, C, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011;96(3):367–74.
17.Oddsson, A, Kristinsson, SY, Helgason, H, Gudbjartsson, DF, Masson, G, Sigurdsson, A, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371–4.
18.Jager, R, Harutyunyan, AS, Rumi, E, Pietra, D, Berg, T, Olcaydu, D, et al. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. American Journal of Hematology. 2014;89(12):1107–10.
19.Wang, L, Swierczek, SI, Drummond, J, Hickman, K, Kim, SJ, Walker, K, et al. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia. 2014;28(4):935–8.
